CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease
Retrieved on:
Wednesday, April 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry
PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
Key Points:
- In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
- The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
- As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
- Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.